Tying it all together, Siemens Molecular Imaging (MI) University, a fundamental part of MI LifeNet - Siemens' customer care initiative - provides a substantive training resource for Siemens' customers. Today's molecular imaging professionals require continuous education, training and the ability to share results. Designed to be used by the interpreting physician, referring physician and technologist, MI University demonstrates the benefits of hybrid PET*CT and SPECT*CT systems, including when and how hybrid imaging influences patient management, through access to valuable clinical data and detailed case studies; video lectures; product information; and a tool for information exchange among peers.
Availability of FLT to NCI Research Sites
Siemens also recently announced that the National Cancer Institute has filed a cross-reference letter to a Type II Drug Master File that Siemens submitted to the U.S. Food and Drug Administration for its investigational 3'Deoxy-3'[18F] Fluorothymidine (F-18 FLT) imaging biomarker. The cross reference allows F-18 FLT to be produced and used by any principle investigator in an NCI multi-center clinical trial. In addition, the imaging biomarker will be available to independent investigators if they receive NCI approval. F-18 FLT is produced by PETNET Solutions or Molecular Imaging Biomarker Research, both subsidiary companies of Siemens Medical Solutions, Molecular Imaging. The imaging biomarker has been used in studies monitoring the proliferative activity of cancer cells and it is currently being used in Phase-I clinical trials at several research sites.
About Siemens Medical Solutions
Siemens Medical Solutions is one of the world's largest suppliers to
the healthcare industry. The company is a renowned medical solutions
provider with core competence and innovative stren
|SOURCE Siemens Medical Solutions|
Copyright©2007 PR Newswire.
All rights reserved